The patents cover claims that includes the Prelude SkinPrep system, which prepares the skin in a controlled, dermabrasive manner to permit either drug delivery or analyte extraction.

In addition, Echo Therapeutics has received a notice of allowance for Symphony transdermal continuous glucose monitoring system (tCGM) system’s US patent application no. 11/223,971.

The claims in the application include certain aspects of the biosensor in the Symphony tCGM system.

Echo chairman and CEO Patrick Mooney said the issuance of these patents further broadens the company’s already extensive intellectual property portfolio surrounding Prelude and Symphony and represents a valuable asset.

"Furthermore, we expect additional US and foreign patents to issue this year that will provide our products with long-term market value and will add significantly to our shareholder value," Mooney added.